Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?

An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.

Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

Will a TIGIT refocus see the stars finally align for the partners?